Details of the Drug Combination

General Information of Drug Combination (ID: DC2RZJV)

• Drug Combination Name: IT-141 + Carglumic acid
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  IT-141 (DMAYD7O): N.A.
  Carglumic acid (DMCY0TI): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 3.27
  Bliss Independence Score: 3.27
  Loewe Additivity Score: 3.69
  LHighest Single Agent (HSA) Score: 3.69

Molecular Interaction Atlas of This Drug Combination

Indication(s) of IT-141

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

IT-141 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[2]

Indication(s) of Carglumic acid

Disease Entry	ICD 11	Status	REF
Acute hyperammonaemia	5C50.A	Approved	[3]

Carglumic acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Carbamoyl-phosphate synthetase I (CPS1)	TT42M75	CPSM_HUMAN	Activator	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7458).
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.